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Chagas disease
Chagas disease, caused by the parasite Trypanosoma cruzi, is spread by infected insects called triatomine bugs 
and can be life threatening during both the early and late stages of infection. Those with the acute form of the 
disease, which lasts 4–8 weeks, typically either have no symptoms or experience mild illness. Some patients with 
acute disease develop swelling at the site of infection, known as Romaña’s sign. Chagas disease then progresses 
to the chronic phase, which can last for years to decades. Infected persons usually don’t have overt symptoms 
nor know they are infected. Twenty to 30 percent of these persons eventually develop chronic disease, which can 
cause death. Signs and symptoms can include cardiac (such as heart failure) and/or gastrointestinal problems 
(such as dilated esophagus or colon), in addition to an increased risk of stroke. Historically, transmission has been 
concentrated in rural areas of Latin America where poor housing conditions promoted contact with infected bugs. 
However, in the last several decades, successful control programs targeting the bugs have substantially decreased 
transmission rates in rural areas, and large-scale migration has brought infected persons to cities both within and 
outside Latin America.
Chagas disease in the United States
The impact of Chagas disease, once thought to be limited to Latin America (where an estimated 8 million people 
are infected), has moved to the United States, through immigration of persons from Chagas–endemic areas of 
Mexico, Central America, and South America. The estimated number of infected persons living in the United States 
is 300,000 or more, based on estimated disease rates by country of origin. The parasite has long been recognized 
also to occur in local bugs and mammals in the southern regions of the United States, and there have been a few 
reported cases of local transmission in humans. 
Blood screening for Chagas disease
Chagas disease can also be spread through blood transfusion, organ transplantation, and from mother to child. 
National screening of the blood supply was instituted in early 2007. More than 500 donors with T. cruzi infection 
were identified within the first 18 months of testing. However, awareness of Chagas disease among health 
professionals and the general public remains limited.
What is CDC doing to address Chagas disease?
The Centers for Disease Control and Prevention (CDC) has been 
working to assist with international Chagas disease efforts for close 
to two decades. In particular, CDC has worked to develop new 
diagnostic methods and participated in efforts to standardize testing 
internationally, including screening strategies to detect infected 
children. Additionally, CDC has developed novel insecticide methods 
for bug control. CDC also conducts epidemiologic investigations and 
works to identify risks for the progression of the disease.
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CDC is also working to minimize the burden of Chagas disease 
in the United States by providing: 
Clinical support
CDC provides extensive support to physicians and patients nationwide, 
including education about the disease, patient risk factors for infection, 
diagnostic testing, recommendations for appropriate evaluation and 
treatment, and the release of medication. Treatment for Chagas disease is 
available. In the United States, antiparasitic drugs are available only from CDC 
for use under investigational protocols for compassionate treatment. CDC has 
released medication for treatment of more than 350 patients since 2000, the 
majority of those drug releases in the past six years. This recent, substantial 
increase in requests for treatment may reflect growing recognition and 
increasing frequency of testing for Chagas disease in the United States. 
Diagnostic laboratory testing
CDC laboratory staff have worked both nationally and internationally to improve screening strategies and to 
create innovative new diagnostic methods. Current research includes development of techniques to detect 
T. cruzi strain differences and biomarkers indicative of disease. Laboratory scientists have also worked to  
develop new diagnostic procedures to promptly detect transplant–associated and congenital infections to 
prevent disease. 
Outreach and education
CDC is actively working to improve awareness and knowledge of 
Chagas disease among health care providers and the public through: 
 - Developing patient and provider educational material including  
Continuing Medical Education (CME), Continuing Nursing  
Education (CNE), podcasts, fact sheets, and conference exhibits
 - Conducting focus groups, designed to assess Chagas disease 
awareness and understanding among patients
 - Conducting physician surveys on Chagas disease in  
collaboration with both academic institutions  
and professional organizations
 - Expanding information available online from 
CDC and translating material into Spanish, 
including information on triatomine  
bugs in the U.S.
 - Organizing pre-meeting clinical courses on 
Chagas disease at annual conferences 
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Surveillance
Currently, states are not required by federal law to report cases of Chagas disease. 
However, Chagas disease is reportable by state mandate in Arizona, Massachusetts, 
Tennessee, and Texas. At this time, there are no plans to add Chagas disease to the 
list of diseases which are nationally notifiable. However, CDC is working to establish 
national surveillance to describe the prevalence of disease in order to better  
inform and support public health response to Chagas disease. Part of that 
surveillance involves results of blood donor testing which is reported on the 
American Association of Blood Banks (AABB) website and may be accessed at 
http://www.aabb.org/programs/biovigilance/Pages/chagas.aspx 
Future direction 
There is still more that can be done to prevent and control the spread of  
Chagas disease including:
 - Increasing awareness of the disease among Hispanic immigrants and  
the physicians who care for them, to help ensure early diagnosis and  
appropriate treatment
 - Participating in international networks to improve and standardize  
Chagas disease diagnostics
 - Defining the risk factors for acquiring Chagas disease in the United States.  
Currently there is very limited data that can be used to determine the  
risk of congenital, transplant, transfusion, and vector-borne infection
 - Determining the cardiac and gastrointestinal burden of disease to 
assess the health impact on the population
 - Establishing a system to monitor trends and detect increases in new  
cases of Chagas disease in the United States, which includes 
increasing public health testing capacity
For more information
on Chagas disease, please visit
http://www.cdc.gov/parasites/chagas (English)
http://www.cdc.gov/parasites/chagas/es/ (Spanish)
or call 1-800-CDC-INFO
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